Zimberelimab
As of the edition of 20 October 2026, Zimberelimab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Antibody
- Registered trials
- 70, 5 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Zimberelimab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 19 | 7 | 10 | 2 |
| Phase 2 | 45 | 4 | 30 | 3 |
| Phase 3 | 6 | 1 | 4 | 0 |
| All trials | 70 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Guangzhou Gloria Biosciences | Lead sponsor of trials | 2017 to now |
| Arcus Biosciences | Lead sponsor of trials | 2018 to now |
| Gilead Sciences | Lead sponsor of trials | 2018 to now |
| Taiho | Lead sponsor of trials | 2021 to now |
| Coherus Oncology | Lead sponsor of trials | 2022 to now |
| RemeGen | Lead sponsor of trials | 2024 to now |